ZYVOX for ORAL SUSP Rx
Generic Name and Formulations:
Linezolid 100mg/5mL; pwd for reconstitution; orange flavor; contains phenylalanine.
Indications for ZYVOX for ORAL SUSP:
Susceptible vancomycin-resistant E. faecium (VREF) infections, nosocomial and community-acquired pneumonia, complicated skin and skin structure infections (including diabetic foot infections) without osteomyelitis, uncomplicated skin and skin structure infections.
Infuse inj over 30–120 mins; switch to oral form when appropriate. VREF: 600mg every 12hrs for 14–28 days. Pneumonia, complicated skin and skin structure: 600mg every 12hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): 12–17yrs: 600mg every 12hrs; >17yrs: 400mg every 12hrs; both for 10–14 days. MRSA: 600mg every 12hrs.
Infuse inj over 30–120 mins; switch to oral form when appropriate. Neonates <7 days: see full labeling. 0–11yrs: VREF: 10mg/kg every 8hrs for 14–28 days; pneumonia, complicated skin and skin structure: 10mg/kg every 8hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): <5yrs: 10mg/kg every 8hrs; 5–11yrs: 10mg/kg every 12hrs; both for 10–14 days.
During or within 2 weeks of MAOIs (eg, phenelzine, isocarboxazid).
Not for treating catheter-related bloodstream infections or catheter-site infections. Uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome: not recommended. History of seizures. Monitor CBC's weekly (esp. if otherwise at risk). Consider discontinuing if myelosuppression occurs or worsens. Therapy >28 days. Peripheral and optic neuropathy. Monitor visual function if treatment ≥3 months and if new visual symptoms occur. Diabetes; monitor for hypoglycemia, if occurs, reduce dose or discontinue. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Concomitant sympathomimetics (eg, pseudoephedrine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergics (eg, dopamine, dobutamine): not recommended. Risk of serotonin syndrome with concomitant SSRIs, trycyclic antidepressants, triptans, meperidine, bupropion, or buspirone. Avoid large amounts of dietary tyramine (keep <100mg/meal). May be antagonized by carbamazepine, phenytoin, phenobarbital. Caution with myelosuppressants.
Diarrhea, vomiting, nausea, anemia, headache, rash, dizziness, pruritus, tongue discoloration, taste alteration; myelosuppression (eg, anemia, thrombocytopenia), lactic acidosis, C.difficile-associated diarrhea, hypoglycemia, blurred vision, convulsion.
Tabs, Inj (YES); susp (NO)
Tabs—20, 100; Susp—150mL; Inj (100mL, 200mL, 300mL)—1
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression